Moleculin Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

Commitments and Contingencies (Details Textual) - USD ($)				1 Months Ended					12 Months Ended
	May 02, 2016	Nov. 02, 2015	Oct. 08, 2015	Oct. 07, 2016	Aug. 19, 2016	May 31, 2016	Feb. 29, 2016	Oct. 19, 2015	Dec. 31, 2016	Jun. 30, 2016	Apr. 30, 2016	Jan. 31, 2016	Dec. 31, 2015	Oct. 31, 2015	Aug. 31, 2015
Loss Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						107,802
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 7.50
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities						$ 1,000,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable						750,000
Deferred Compensation Liability, Classified, Noncurrent									$ 87,500				$ 0
Milestone Payment Description								The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States - $600,000.
Mr. Louis [Member]
Loss Contingencies [Line Items]
Severance Costs				$ 100,000
Separation Agreement Description				Pursuant to the Separation Agreement, Mr. Ploth will be permitted to exercise 25% of the options to purchase common stock granted to him in December 2015, or 50,000 shares, until May 2020.
Moleculin LLC [Member]
Loss Contingencies [Line Items]
Payments for Other Fees						306,186
Patent Law Firm [Member] \| Minimum Fee and patent Expenses [Member]
Loss Contingencies [Line Items]
Contractual Obligation, Total													42,504	$ 65,504
Bonwick Capital Partners LLC [Member]
Loss Contingencies [Line Items]
Letter Agreements Terms							the Company agreed to: a) pay success fees equal to 7% of the gross proceeds from any form of financing; and b) issue five-year warrants to purchase 7% of the Companys equity securities sold with a cashless exercise provision, exercisable at 125% of the price per share of the Companys common stock paid by investors in the transaction. In addition, the Company agreed to reimburse Bonwick for all of its out-of-pocket expenses incurred in connection with the offering, not to exceed $25,000, and fees and expenses of their counsel not to exceed $100,000.
Success Fee Percentage							7.00%
Class of Warrant or Right, Percentage of Securities Called by Warrants or Rights							7.00%
Class of Warrant or Right, Exercise Price Percentage Threshold							125.00%
Payments for Underwriting Expense							$ 50,000
Bonwick Capital Partners LLC [Member] \| IPO [Member]
Loss Contingencies [Line Items]
Reimburement of Expenses						6,266
Payments of Stock Issuance Costs						$ 646,872
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						107,802
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 7.50
Bonwick Capital Partners LLC [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Reimbursement Payable, Offering Costs							25,000
Reimbursement Payable, Fees and Expenses of Counsel							$ 100,000
MD Anderson [Member] \| Minimum Fee and patent Expenses [Member]
Loss Contingencies [Line Items]
Contractual Obligation, Total			$ 98,108										$ 45,000	98,108
MD Anderson [Member] \| Minimum Annual Royalty [Member]
Loss Contingencies [Line Items]
Contractual Obligation, Total			65,504
Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Officers' Compensation									300,000
Deferred Compensation Liability, Classified, Noncurrent									$ 87,500	$ 12,500
Chief Financial Officer and Executive Vice President [Member]
Loss Contingencies [Line Items]
Officers' Compensation					$ 250,000
Deferred Compensation Arrangement with Individual, Maximum Contractual Term					3 years
Chief Financial Officer and Executive Vice President [Member] \| Employee Stock Option [Member]
Loss Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Shares Issued					400,000
Deferred Compensation Arrangement with Individual, Exercise Price					$ 5.85
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Patent and Technology License Agreement [Member]
Loss Contingencies [Line Items]
Contractual Obligation, Total											$ 91,186	$ 175,000		$ 125,000
Payments for Royalties		$ 125,000
License Agreement, Maintenance Fee	$ 20,000
License Agreement, Maintenance Fee Annual Increase	10,000
Payments for Other Fees			300,000
License Agreement, Maintenance Fee - Maximum Payable Per Year	$ 100,000
Patent and Technology License Agreement [Member] \| Servicing Fee payable [Member]
Loss Contingencies [Line Items]
Contractual Obligation, Due First Anniversary April 2, 2013															$ 10,000
Contractual Obligation, Due Second Anniversary															20,000
Contractual Obligation, Due Third Anniversary															40,000
Contractual Obligation, Due Fourth Anniversary															60,000
Contractual Obligation, Due Fifth Anniversary															80,000
Contractual Obligation, Due Sixth Anniversary															100,000
Patent and Technology License Agreement [Member] \| Minimum Annual Royalty [Member]
Loss Contingencies [Line Items]
Contractual Obligation, Due in Next Fiscal Year, After Product Approval															200,000
Contractual Obligation, Due in Second Year, After Product Approval															400,000
Contractual Obligation, Due in Third Year, After Product Approval															$ 600,000
Patent and Technology License Agreement [Member] \| Letter Agreement [Member]
Loss Contingencies [Line Items]
Payments for Other Fees			$ 691,186